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INFLUENCE OF SEROTONIN RELATED GENES ON TA-
MOXIFEN INDUCED HOT FLASHES AND RESPONSIVENESS
TO SELECTIVE SEROTONIN REUPTAKE INHIBITORS. J.
Hwang, MD, Y. Jin, MD, A. M. Storniolo, MD, D. F. Hayes, MD, L.
Li, PhD, V. Stearn, MD, T. C. Skaar, PhD, D. A. Flockhart, MD,
PhD, Seoul National University Bundang Hospital, Korea, Clinical
Pharmacology Hematology/Oncology, Indiana University, Univer-
sity of Michigan, Johns Hopkins University, Indianapolis, IN.
BACKGROUND: Hot flashes are the most common side effect in
women treated with tamoxifen, but their severity is variable. Since
serotonin is thought to be involved in hot flashes, we determined the
association of hot flashes with polymorphisms of four serotonin
related genes in women taking tamoxifen.
METHODS: We studied 190 breast cancer patients before and
after 1 & 4 months of tamoxifen therapy. At each time point, hot flash
frequency and severity and current medication were recorded. The
5-HTTLPR variant in serotonin transporter, C(-1019)G polymor-
phism in serotonin 1A receptor (HTR1A), T102C in serotonin 2A
receptor (HTR2A), and A218C in tryptophan hydroxylase1 (TPH1)
were studied. Associations were analyzed by log-linear regression
with repeated measures.
RESULTS: Before tamoxifen therapy, premenopausal subjects
with previous chemotherapy with 5-HTTLPR ss genotype had higher
hot flash scores than those with ll or Is genotype (P0.04). In peri &
postmenopausal subjects, hot flash scores of ss genotype increased
more during tamoxifen therapy (P0.02) and HTR2A TT genotype
had higher hot flash scores before (P 0.02) and after (P0.001)
tamoxifen therapy than TC and CC. SSRIs appeared to be less
effective at reducing hot flashes in HTR2A TT genotype patients
(P0.04). HTR1A and TPH1 were not associated with hot flashes.
CONCLUSIONS: A pharmacogenetic interaction between ta-
moxifen and the serotonin transporter and HTR2A may contribute to
the variability in tamoxifen induced hot flashes.
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STRUCTURE-ACTIVITY RELATIONSHIPS AND IN SILICO
MODELING OF ACTIVATION OF THE HUMAN PREGNANE X
AND VITAMIN D RECEPTORS BY BILE SALTS AND STEROID
COMPOUNDS. M. D. Krasowski, MD, PhD, E. J. Reschly, PhD, M.
Iyer, PhD, University of Pittsburgh, Pittsburgh, PA.
BACKGROUND/AIMS: The pregnane X receptor (PXR;
NR1I2) is a nuclear hormone receptor with broad ligand specificity
that regulates the metabolism and elimination of bile salts, steroid
hormones, and xenobiotics. PXR is closely related to the vitamin D
receptor (VDR; NR1I1), although VDR has much narrower ligand
specificity. The purpose of the study was to compare structure-
activity relationships for activation of the human PXR and VDR by
47 bile salts and 71 steroid hormones and to use in silico modeling to
determine the role of ligand-binding pocket size, ligand orientation,
and receptor flexibility in determining ligand activity.
METHODS: Activation of human PXR and human VDR was
studied using an in vitro assay in HepG2 liver cells. In silico mod-
eling of human PXR ligand activation was performed with 4D-QSAR
analysis (Chem21 Group, Inc.) and comparative molecular field anal-
ysis (SYBYL with CoMFA, Tripos, Inc.).
RESULTS: Human PXR was activated by 25/47 bile salts and
58/71 steroids tested while human VDR was only activated by 5 bile
salts. The concentrations of bile salts and steroids that activate human
PXR are at least one, and often several, orders of magnitude higher
than concentrations circulating in plasma in healthy humans.
CONCLUSIONS: Human PXR has very broad specificity but low
affinity for bile salts and steroid compounds, consistent with a role in
detecting toxic levels of these compounds. This broad specificity
present significant challenges for in silico prediction of human PXR
ligand activation.
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INFLUENCE OF OATP-C GENOTYPE ON THE PHARMACO-
KINETICS OF ROSUVASTATIN. H. Oh, BS, J. Choi, MD, M. Lee,
MD, PhD, K. Park, PhD, MD, Yonsei University College of Medi-
cine, Dept of Pharmacology, Seoul, Republic of Korea.
BACKGROUND: To investigate the influence of the Organic
Anion-Transporting Polypeptide C(OATP-C) genotype on rosuvas-
tatin pharmacokinetics.
METHODS: 121 healthy Koreans were examined with regard to
the OATP-C1b/1b, OATP-C1b/15, and OATP-C15/15 geno-
type. The 3 genotypes were selected according to the study with 120
Japanese on pravastatin, where significant pharmacokinetic differ-
ences were observed among the 3 genotypes. Among 121 subjects, 13
subjects, 6 for 1b/1b, 6 for 1b/15, and 1 for 15/15, were
selected for the rosuvastatin pharmacokinetic study of a single oral
dose of 10mg. Blood samples were collected at 0, 0.5, 1, 3, 5, 7, 10,
15, 24, 48, 72hr after dosing. Using a noncompartment method, area
under concentration-time (AUC), maximum concentration (Cmax),
time to maximum concentration (Tmax) were calculated for the 3
genotypes.
RESULTS: AUC for 15/15 was 201.4 ngh/ml, whereas those
for the other 2 genotypes were about a half (11157 for 1b/1b and
10640 for 1b/15, value as mean  SD) without significant
difference each other (p0.85). For 15/15, Cmax was also twice as
much, but Tmax was smallest. For lactone, 1b/1b showed the
highest value of AUC and Cmax among the 3 genotypes.
CONCLUSIONS: The results show that the genomic difference
of OATP-C can influence rosuvastatin pharmacokinetics. A study
with more subjects would be necessary to further support our results.
Influence on pharmacodynamics and other genetic variations such as
MRP2 and BCRP may also need to be investigated.
PII-24
LOW FREQUENCY OF THE CYP2D7-ACTIVATING 138delT
POLYMORPHISM IN DIFFERENT ETHNIC GROUPS. A. Bha-
thena, PhD, T. Mueller, MS, D. R. Grimm, PhD, K. B. Idler, BS,
A. C. Tsurutani, BS, D. A. Katz, PhD, Abbott Laboratories, Abbott
Park, IL.
BACKGROUND: Polymorphisms within cytochrome P450 2D6
(CYP2D6) result in different metabolizer phenotypes, but some dis-
cordance suggests the possibility of additional unknown alleles or
factors contributing to metabolism. A recent study showed a high
frequency frameshift-causing deletion, CYP2D7 138delT, which con-
verted the CYP2D7 pseudogene to a functional gene within the
brain.1 The high frequency of the deletion and the resulting CYP2D7
expression could have important implications for brain-specific me-
tabolism of psychoactive substances. Our goal was to determine the
frequency of this deletion in a larger ethnically diverse population.
METHODS: The CYP2D7 138delT genotypes for 163 Cauca-
sians, 95 East Asians, 50 South Asians, 68 Hispanic Latinos, and 68
African Americans were determined by Pyrosequencing.
RESULTS: The 138delT allele was observed at a frequency of
1.0% in East Asians and 0.74% in Hispanic Latinos. The deletion was
not observed in the other ethnic populations.
CONCLUSIONS: The very low frequency of the CYP2D7
138delT polymorphism in our panel is in contrast to the high fre-
quency (50%) reported in the Indian population.1 Our results suggest
that CYP2D7 138delT is unlikely to be highly relevant for population
variation of pharmacokinetics or drug response.
1Pai et al. (2004) J Biol Chem 279, 27383-27389.
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